Pheast Raises $76M In Series A Funding To Train The Immune System To Feast On Cancer

Apr 26, 2022•over 3 years ago

Amount Raised

$76 Million

Round Type

series a

Palo Alto

Description

Pheast Therapeutics, a company developing novel checkpoint therapies to fight cancer, today announced it has raised $76 million in Series A funding round led by Catalio Capital Management and ARCH Venture Partners. Alexandria Venture Investments and Risk and Reward (R2) also participated. Pheast plans to use the funds to expand its management, scientific, and administrative teams, as well as towards R&D to advance its pipeline of innate immune checkpoint inhibitors towards the clinic.

Company Information

Company

Pheast

Location

Palo Alto, California, United States

About

Pheast is a pre-clinical stage immuno-oncology company focused on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. Founded in 2020 and led by scientific experts in innate immunity and cancer immunotherapy, Pheast is aiming to develop novel therapies for some of the most difficult-to-treat and aggressive cancers, as well as women's cancers including ovarian cancer and breast cancer. Pheast can be found online at Pheast.com and on LinkedIn.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Pheast Raises $76M In Series A Funding To Train The Immune System To Feast On Cancer

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information